/NTLA
NTLA Stock - Intellia Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$9.23+3.94%
+$0.35 (+3.94%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.18
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.35
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+122.1%upside
Target: $20.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NTLA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.14 – $9.32
TARGET (TP)$20.50
STOP LOSS$8.49
RISK/REWARD1:15.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.13
52W High$28.25
52W Low$5.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $57.88M | $36.27M | $52.12M | $33.05M | $57.99M |
| Gross Profit | $47.59M | $27.30M | $44.55M | $26.16M | $-92,414,000 |
| Gross Margin | 82.2% | 75.3% | 85.5% | 79.2% | -159.4% |
| Operating Income | $-534,263,000 | $-515,291,000 | $-458,164,000 | $-267,850,000 | $-136,583,000 |
| Net Income | $-519,021,000 | $-481,192,000 | $-474,186,000 | $-267,892,000 | $-134,231,000 |
| Net Margin | -896.8% | -1326.5% | -909.8% | -810.5% | -231.5% |
| EPS | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 |
Company Overview
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
53%
Hold / Neutral
5
33%
Sell / Underperform
2
13%
Analyst Consensus🟡 Mixed
8 Bullish7 Neutral/Bearish
Price Targets
$43
Average Target
↑ 365.4% Upside
Now
$5
Low
$43
Average
$100
High
Based on 21 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 12th 2025 | Wolfe Research | Downgrade | Peer Perform | - |
| November 11th 2025 | Evercore ISI | Downgrade | In-line | $8 |
| November 7th 2025 | JP Morgan | Downgrade | Underweight | $5 |
| October 28th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $14 |
| October 28th 2025 | Bernstein | Downgrade | Market Perform | - |
| October 27th 2025 | William Blair | Downgrade | Market Perform | - |
| October 27th 2025 | Guggenheim | Downgrade | Neutral | - |
| October 6th 2025 | Citizens JMP | Upgrade | Mkt Outperform | $33 |
| April 21st 2025 | Wolfe Research | Upgrade | Outperform | $21 |
| March 5th 2025 | H.C. Wainwright | Initiation | Buy | $30 |
| February 28th 2025 | JP Morgan | Downgrade | Neutral | $13← $45 |
| February 28th 2025 | Goldman | Downgrade | Sell | $9 |
| January 27th 2025 | Morgan Stanley | Downgrade | Equal Weight | $11← $56 |
| February 23rd 2024 | Goldman | Downgrade | Neutral | $32← $136 |
| February 15th 2024 | Wolfe Research | Initiation | Peer Perform | - |
Earnings History & Surprises
NTLABeat Rate
50%
Last 18 quarters
Avg Surprise
-6.8%
EPS vs Estimate
Beats / Misses
9/8
1 met exactly
Latest EPS
$-0.92
Q4 2025
EPS Surprise History
Q1 24
+0.7%
$-1.46vs$-1.47
Q2 24
+21.5%
$-1.06vs$-1.35
Q3 24
-8.3%
$-1.31vs$-1.21
Q4 24
+2.2%
$-1.34vs$-1.37
Q1 25
+6.1%
$-1.24vs$-1.32
Q2 25
+12.7%
$-1.10vs$-1.26
Q3 25
+3.9%
$-0.99vs$-1.03
Q4 25
+9.8%
$-0.92vs$-1.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.99 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.02 | $-0.92 | +9.8% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-1.03 | $-0.99 | +3.9% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-1.26 | $-1.10 | +12.7% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-1.32 | $-1.24 | +6.1% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-1.37 | $-1.34 | +2.2% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.21 | $-1.31 | -8.3% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-1.35 | $-1.06 | +21.5% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-1.47 | $-1.46 | +0.7% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-1.52 | $-1.38 | +9.2% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-1.32 | $-1.40 | -6.1% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-1.41 | $-1.17 | +17.0% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-1.40 | $-1.40 | 0.0% | = MET |
Q4 2022 | Nov 3, 2022 | $-1.31 | $-1.49 | -13.7% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-1.31 | $-1.33 | -1.5% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-1.11 | $-1.96 | -76.6% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.91 | $-1.09 | -19.8% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.85 | $-0.97 | -14.1% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.61 | $-1.01 | -65.6% | ✗ MISS |
Latest News
Wolfe Research Downgrades Intellia Therapeutics to Peer Perform
📉 NegativeBenzinga•Nov 12, 2025, 12:00 PM
Jones Trading Downgrades Intellia Therapeutics to Hold
📉 NegativeBenzinga•Nov 11, 2025, 07:54 PM
Evercore ISI Group Downgrades Intellia Therapeutics to In-Line, Lowers Price Target to $8
📉 NegativeBenzinga•Nov 11, 2025, 10:15 AM
Intellia Therapeutics Presents Follow-Up Data From Ongoing Phase 1 Clinical Trial Of Investigational Product Nex-Z In Patients With Transthyretin Amyloidosis With Cardiomyopathy, At AHA 2025
➖ NeutralBenzinga•Nov 10, 2025, 08:22 PM
Truist Securities Reiterates Buy on Intellia Therapeutics, Lowers Price Target to $14
➖ NeutralBenzinga•Nov 10, 2025, 04:45 PM
HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Lowers Price Target to $15
➖ NeutralBenzinga•Nov 10, 2025, 12:32 PM
Reported Saturday, Intellia Therapeutics Pooled Phase 1/2 Data Show 97% Of Patients Attack-Free And LTP-Free After One-Time 50mg Dose Of Lonvoguran Ziclumeran In Hereditary Angioedema
📈 PositiveBenzinga•Nov 10, 2025, 08:56 AM
Chardan Capital Maintains Buy on Intellia Therapeutics, Lowers Price Target to $26
📈 PositiveBenzinga•Nov 7, 2025, 11:10 PM
RBC Capital Maintains Sector Perform on Intellia Therapeutics, Lowers Price Target to $9
📉 NegativeBenzinga•Nov 7, 2025, 07:10 PM
Wells Fargo Maintains Equal-Weight on Intellia Therapeutics, Lowers Price Target to $12
📉 NegativeBenzinga•Nov 7, 2025, 06:56 PM
Barclays Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $14
➖ NeutralBenzinga•Nov 7, 2025, 03:28 PM•Also:
Wedbush Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $7
➖ NeutralBenzinga•Nov 7, 2025, 03:08 PM
Citizens Maintains Market Outperform on Intellia Therapeutics, Lowers Price Target to $21
➖ NeutralBenzinga•Nov 7, 2025, 01:52 PM
Intellia Therapeutics shares are trading lower after reporting mixed Q3 financials. JP Morgan downgraded the stock from Neutral to Underweight and lowered its price target from $12 to $5.
📉 NegativeBenzinga•Nov 7, 2025, 01:46 PM
JP Morgan Downgrades Intellia Therapeutics to Underweight, Lowers Price Target to $5
📉 NegativeBenzinga•Nov 7, 2025, 12:15 PM
Intellia plunges as Q3 updates indicate patient death in gene editing trial
📉 NegativeSeeking Alpha•Nov 7, 2025, 12:03 PM
Intellia Therapeutics shares are trading lower after reporting mixed Q3 financials.
📉 NegativeBenzinga•Nov 6, 2025, 10:16 PM
Intellia Therapeutics Q3 EPS $(0.92) Beats $(0.99) Estimate, Sales $13.782M Miss $15.185M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 10:05 PM
HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Lowers Price Target to $18
➖ NeutralBenzinga•Oct 30, 2025, 04:15 PM
Market-Moving News for October 30th
➖ NeutralBenzinga•Oct 30, 2025, 11:16 AM•Also: ,
Frequently Asked Questions about NTLA
What is NTLA's current stock price?
Intellia Therapeutics, Inc. (NTLA) is currently trading at $9.23 per share. The stock has moved +3.94% today.
What is the analyst price target for NTLA?
The average analyst price target for NTLA is $20.50, based on 1 analyst.
What sector is Intellia Therapeutics, Inc. in?
Intellia Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NTLA's market cap?
Intellia Therapeutics, Inc. has a market capitalization of $0.97 billion, making it a small-cap company.
Does NTLA pay dividends?
No, Intellia Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCRX
BioCryst Pharmaceuticals, Inc.
$7.41
Mkt Cap: $1.6B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
STOK
Stoke Therapeutics, Inc.
$31.96
Mkt Cap: $1.8B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
ZBIO
Zenas BioPharma, Inc.
$36.15
Mkt Cap: $1.5B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to NTLA for comparison